Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update


Life Sciences Company Hits Sales Milestone with Livestock Product
News Update


With this development, the Canadian firm entered a new geography and an additional market segment.

Avivagen Inc. (VIV:TSX.V) received its first order from Thailand for OxC-beta Livestock, a fully oxidized beta carotene (OxBC) premix for adding to certain animal feeds to improve the health of the livestock. The company has shown it to be "effective and economic in replacing the antibiotics commonly added to livestock feeds," noted a news release.

Also a first, the proprietary product will be used in sow feeds. "Commercial validation in Thailand is expected to positively influence adoption for use in sows in other countries," the release indicated.

Sows comprise a significant portion of the swine feed market, and they require a large amount of feed, with one sow consuming about 1 metric ton of it annually. For instance, Thailand is home to an estimated 860,000 sows, and the count in the Philippines is around 560,000. Thus, the sow market presents significant additional market potential for sales of OxC-beta Livestock.

In the Philippines, where OxC-beta Livestock has been sold for a year, uptake of it continues to increase. Whereas in 2016, livestock consumed 11.75 million metric tonnes of feed annually, it now consumes 17 million metric tonnes. This suggests similar growth may also happen in Thailand. Last week Avivagen announced the sale of 2 metric tonnes of OxC-beta Livestock in the Philippines.

Along with the Philippines and Thailand, OxC-beta Livestock is currently for sale in Taiwan and New Zealand.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen Inc. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen Inc. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen Inc., a company mentioned in this article.

Want to read more about Nutraceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe